Transcriptional shift identifies a set of genes driving breast cancer chemoresistance.

ABSTRACT:

Background

Distant recurrences after antineoplastic treatment remain a serious problem for breast cancer clinical management, which threats patients' life. Systemic therapy is administered to eradicate cancer cells from the organism, both at the site of the primary tumor and at any other potential location. Despite this intervention, a significant proportion of breast cancer patients relapse even many years after their primary tumor has been successfully treated according to current clinical standards, evidencing the existence of a chemoresistant cell subpopulation originating from the primary tumor.

Methods/findings

To identify key molecules and signaling pathways which drive breast cancer chemoresistance we performed gene expression analysis before and after anthracycline

SUBMITTER: Vera-Ramirez L 

PROVIDER: S-EPMC3542325 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature